HOWLHIGH SIGNALRISK10-K

HOWL has added explicit going concern language stating substantial doubt about their ability to continue operations for at least twelve months, while their cash position has deteriorated significantly.

The addition of going concern warnings represents a material escalation in the company's risk profile, indicating management believes there is substantial doubt about their ability to continue operations without additional capital. This is compounded by their ongoing capital raise efforts with no assurance of success, creating immediate liquidity risk for investors.

Comparing 2026-03-27 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

HOWL's financial position has deteriorated substantially, with cash declining 48.6% to $57.0M while current liabilities surged 138.1% to $36.1M, resulting in stockholders' equity plummeting 66.2% to just $24.8M. Despite some improvement in operating losses (17.6% reduction), the company burned through over $50M in cash while adding significant near-term obligations. The overall picture signals a company in financial distress with a rapidly shrinking cash runway and mounting short-term liabilities, explaining the new going concern qualification.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+138.1%
$15.2M→$36.1M

Current liabilities surged 138.1% — significant near-term obligations; verify ability to meet short-term debt.

Stockholders Equity
Balance Sheet
-66.2%
$73.4M→$24.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-48.6%
$111.0M→$57.0M

Cash declined 48.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-48.2%
$113.1M→$58.6M

Current assets declined 48.2% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-45.3%
$126.9M→$69.4M

Total assets contracted 45.3% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-20.6%
$56.4M→$44.8M

R&D spending cut 20.6% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+17.6%
-$73.6M→-$60.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Liabilities
Balance Sheet
-16.7%
$53.5M→$44.6M

Liabilities reduced 16.7% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
+13.7%
-$70.5M→-$60.8M

Net income grew 13.7% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-11
ADDED
As of March 20, 2026, there were 48,596,817 shares of common stock, $0.0001 par value per share, outstanding.
These risks include, but are not limited to, the following: We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these consolidated financial statements are issued in this Annual Report.
We are currently evaluating strategies to raise additional capital, however, there can be no assurances that we will be successful in mitigating the conditions which raise substantial doubt about our ability to continue as a going concern in the near term, if at all.
Our evaluation of strategic alternatives and ability to extend our capital resources.
We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
+7 more — sign up free →
REMOVED
As of March 5, 2025, there were 44,827,159 shares of common stock, $0.0001 par value per share, outstanding.
These risks include, but are not limited to, the following: We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
We will need to obtain substantial additional funding to finance our operations and complete the development and any commercialization of WTX-124, WTX-330 and any future product candidates.
We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
In November 2023, we announced preliminary first-in-human clinical data from the initial monotherapy dose-escalation cohorts in the Phase 1/1b clinical trial establishing proof of mechanism for WTX-124 and proof of concept for our INDUKINE design, and included assessments of safety and tolerability, pharmacokinetics, relevant biomarkers and preliminary antitumor activity.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →